⌘K

08:06:05·171d

SECFilingvia Quantisnow

NexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

ByQuantisnow·Wall Street's wire, on your screen.

NXGL· NexGel Inc

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

NXGL
NexGel Inc
Health Care

Recent analyst ratings

Feb 25UpdateMaxim Group$6.00

Related

SEC2d
Amendment: SEC Form 10-K/A filed by NexGel Inc
SEC2d
NexGel Inc filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
PR5d
NEXGEL Appoints Ian Blackman as Chief Financial Officer
SEC8d
NexGel Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
SEC11d
NexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
PR11d
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
PR15d
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
PR17d
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction